Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24961015 | 0.91 | CTSL (0.49) | CTSLCTSB | |
| SCHEMBL24960416 | 0.90 | CTSL (0.60) | CTSLCTSB | |
| SCHEMBL24960419 | 0.89 | — | — | |
| SCHEMBL24961198 | 0.89 | F2R (0.52) | — | |
| SCHEMBL24960974 | 0.85 | CTSL (0.62) | CTSLCTSB | |
| SCHEMBL26224158 | 0.84 | CTSL (0.47) | CTSLCTSB | |
| SCHEMBL24960973 | 0.83 | — | — | |
| SCHEMBL24961010 | 0.81 | — | — | |
| SCHEMBL24691243 | 0.80 | CTSL (0.63) | CTSLCTSB | |
| SCHEMBL30002344 | 0.80 | CTSL (0.63) | CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11753373-B2 | Protease inhibitors as antivirals | ACEA Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026438-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-11753373-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | CTSL 4/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.